{"entity":{"id":"nct07450183","kind":"trial","name":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","aka":[],"tldr":"A phase 2 trial of cemiplimab in lung cancer, run by Henry Ford Health System, not yet recruiting.","summary":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 is a phase 2, interventional study registered as NCT07450183 by Henry Ford Health System, with a registry enrolment figure of 33 participants, started 2027-01-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Cemiplimab; Adjuvant chemotherapy. Conditions listed: Lung Cancer (NSCLC). Primary outcome: Pathologic Complete Response Rate. Lung eligibility wording from the registry: \"* Patient diagnosed with early-stage resectable stage II to IIIA squamous or non-squamous, operable treatment naïve NSCLC with PD-L1 TPS ≥50%\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07450183","url":"https://clinicaltrials.gov/study/NCT07450183"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07450183","phase":"2","setting":"Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%","sponsor":"Henry Ford Health System","enrolled":33,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07450183/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}